Focus: Aequita Bioworks is a pre-revenue biotech focused on developing monoclonal antibodies targeting muscle loss reduction in metabolic diseases. The company operates as a focused pipeline player in the San Carlos biotech ecosystem.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Aequita Bioworks to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
No open positions listed yet. Check their careers page directly.
Help build intelligence for Aequita Bioworks
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Aequita Bioworks's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Lipid nanoparticles with aptamers enable targeted mRNA delivery to CD4⁺ T cells.
Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization.
Process Development of Site-Specific Antibody-Drug Conjugates.
Nanoscale elemental mapping reveals the effect of light and temperature on Gephyrocapsa huxleyi coccoliths.
A growth-coupled progesterone-responsive biosensor for high-throughput microfluidic screening in Saccharomyces cerevisiae.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo